ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

被引：0
|
作者：
Fernandez-Barcelo, C. [1 ]
Abbas, I
Botella, X. [2 ]
Aguilo Domingo, M. [2 ]
Cots, F. [3 ]
Siles Cuesta, C. [3 ]
Arriola, E. [3 ]
Gas Lopez, M. E. [4 ]
Lopez Gomez, C. [4 ]
Juan-Vidal, O. [5 ]
Planellas, L. [6 ]
Lloansi, A. [6 ]
Sanchez, J. [1 ]
Reguart, N. [1 ]
Sampietro-Colom, L. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Consorci Sanitari Terrassa, Terrassa, Spain
[3] Hosp Mar CIBERONC, Barcelona, Spain
[4] Hlth Res Inst Hosp La Fe, Valencia, Spain
[5] Hosp La Fe Valencia, Valencia, Spain
[6] Amgen SA, Barcelona, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD89
引用
收藏
页码：S521 / S521
页数：1
相关论文
共 50 条
  • [41] EGFR mutation and response to chemotherapy in non-small-cell lung cancer (NSCLC) patients.
    Lee, KH
    Han, SW
    Jeong, S
    Kim, DW
    Chung, DH
    Im, SA
    Kim, TY
    Heo, DS
    Bang, YJ
    Kim, NK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [42] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
  • [43] KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer
    Suzuki, Shinichiro
    Yonesaka, Kimio
    CANCER SCIENCE, 2022, 113 : 1260 - 1260
  • [44] Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.
    May, Michael S.
    Wooster, Margaux
    May, Benjamin
    Shu, Catherine A.
    Henick, Brian S.
    Stoopler, Mark
    Smith-Marrone, Stephanie
    Saqi, Anjali
    Mansukhani, Mahesh M.
    Riely, Gregory J.
    Hershman, Dawn L.
    Herzberg, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring KRAS G12V mutations
    John, Felix
    Ruge, Lea
    Scharpenseel, Heather
    Siemanowski, Janna
    Fassunke, Jana
    Riedel, Richard
    Michels, Sebastian Yves Friedrich
    Fischer, Rieke Nila
    Rasokat, Anna
    Schulte, Wolfgang
    Franke, Karl-Josef
    Graeven, Ullrich
    Kappes, Jutta
    Kron, Anna
    Siebolts, Udo
    Merkelbach-Bruse, Sabine
    Buettner, Reinhard
    Wolf, Juergen
    Scheffler, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation
    Lee, C.
    Pavlakis, N.
    Zhou, D. D. -X.
    Brown, C.
    Hughes, B. G. M.
    Yip, S.
    Bray, V. J.
    Daley, F. T.
    Roberts-Thomson, R.
    Cummins, M. M.
    John, T.
    Solomon, B. J.
    Mitchell, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S362
  • [47] Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
    Kitai, Hidenori
    Choi, Philip H.
    Yang, Yu C.
    Boyer, Jacob A.
    Whaley, Adele
    Pancholi, Priya
    Thant, Claire
    Reiter, Jason
    Chen, Kevin
    Markov, Vladimir
    Taniguchi, Hirokazu
    Yamaguchi, Rui
    Ebi, Hiromichi
    Evans, James
    Jiang, Jingjing
    Lee, Bianca
    Wildes, David
    de Stanchina, Elisa
    Smith, Jacqueline A. M.
    Singh, Mallika
    Rosen, Neal
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [48] CUSTOMIZING ERLOTINIB IN METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Sirera, R.
    Catot, S.
    Gonzalez-Larriba, J. L.
    Bover, I.
    Alonso, G.
    Valdivia, J.
    Ibeas, R.
    Lianes, P.
    Martinez del Prado, P.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [49] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US
    Zhang, Peng
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
    Skrickova, Jana
    Bortlicek, Zbynek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Tomiskova, Marcela
    Grygarkova, Ivona
    Koubkova, Leona
    Cernovska, Marketa
    Roubec, Jaromir
    Salajka, Frantisek
    Zemanova, Milada
    Coupkova, Helena
    Satankova, Monika
    Marel, Milosalav
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345